FTSE MIB
28.575,90 -132,65 (-0,46%) Dow Jones
33.992,75 -77,67 (-0,23%) Nasdaq
13.214,52 -9,47 (-0,07%) Nikkei 225
32.402,41 -168,62 (-0,52%) Petrolio
89,95 +0,32 (+0,36%) Bitcoin EUR
24.935,85 -90,97 (-0,36%)
Terns Pharmaceuticals, Inc. (TERN)
| Chiusura precedente | 5,31 |
| Aperto | 5,31 |
| Denaro | 5,31 x 900 |
| Lettera | 5,33 x 800 |
| Min-Max giorno | 5,12 - 5,39 |
| Intervallo di 52 settimane | 4,38 - 14,04 |
| Volume | |
| Media Volume | 805.787 |
| Capitalizzazione | 323,681M |
| Beta (5 anni mensile) | -1,01 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,14 |
| Prossima data utili | 07 nov 2023 - 13 nov 2023 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,63 |
GlobeNewswireTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that it has granted as of September 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement A
- GlobeNewswire
Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences
FOSTER CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in September. 2023 Wells Fargo Healthcare Conference
- GlobeNewswire
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
- Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 (THR-β) in NASH, with TERN-501 meeting all primary and secondary endpoints - TERN-701 (allosteric BCR-ABL) Phase 1 clinical trial for CML on track to initiate in second half of 2023; enrollment progress from ongoing China Phase 1 clinical trial presented at 2023 ASCO Annual Meeting - TERN-601 (GLP-1) program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting; on track to ini
